Company news
Cansino Biologics, Inc. Class A (SSE:688185) news
Cansino Biologics, Inc. Class A news releases on 6ix. Latest, Dec 5, 2024: Indicative Announcement on One of Actual Controllers Adjusting H-share Holding…
Press releases — page 2
Indicative Announcement on One of Actual Controllers Adjusting H-share Holding Method and Signing Supplementary Agreement (II) to Concerted Action Agreement
December 4, 2024
Announcement on the Voluntary Disclosure of the Acceptance of the Supplemental Drug Application for the Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)
November 26, 2024
Announcement on Resolution of the 2nd Holders' Meeting of 2023 Employee A-share Ownership Plan
November 25, 2024
Announcement on Convening the Q3 2024 Performance Briefing
November 15, 2024
Report for Q3 2024
October 29, 2024
Voluntary Disclosure on the Approval of Clinical Trial for Recombinant Polio Vaccine in Indonesia
October 9, 2024
Announcement on Participating in the 2024 Semi-Annual Collective Performance Briefing for Pharmaceutical and Biological Products
September 6, 2024
Announcement on Resolutions of the 4th Meeting of the 3rd Board of Supervisors
August 29, 2024
Announcement on Participating in the 2024 Tianjin Region Listed Companies' Semi-Annual Performance Briefing and Online Collective Reception Day Event
August 27, 2024